Drug Trial Radar · NCT00620594
A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer
Last checked: Nov 19, 2026Latest source record: Dec 9, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
183
Actual
Start
Dec 21, 2006
Primary completion
Jan 8, 2013
Study completion Jan 8, 2013
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Feb 21, 2008
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a first-in-human, phase I/Ib clinical research study with BEZ235, an inhibitor of phosphatidylinositol 3'-kinase (PI3K). The study consists of a dose escalation part followed by a safety dose expansion part: Dose escalation part (advanced solid tumors, including patients with breast cancer being treated with trastuzumab): Patients receive oral BEZ235 once daily on days 1-28 of the first course. Courses will repeat every 28 days in the absence of disease progression or unacceptable toxicity. Cohorts of at least 3 patients receive escalating doses of BEZ235, as single agent or in combination with trastuzumab, until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose expected to produce during the first course of treatment dose-limiting toxicity in 33% of patients. Once the MTD has been defined, the safety expansion parts of the trial will be opened for enrollment. Safety dose expansion part (advanced solid tumors, including patients with breast cancer being treated with trastuzumab): Patients will be treated with BEZ235, as single agent or in combination with trastuzumab, given at the MTD, once daily. Treatment of patients will continue until disease progression or occurrence of unacceptable side effects.
Conditions
- Breast Cancer
- Advanced Solid Tumors
- Cowden Syndrome
Interventions
BEZ235Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- determine the maximum Tolerated Dose (MTD) of BEZ235 as single agent and in combination with trastuzumab (Dose escalation part)Time frame: at end of study
- assess the safety & tolerability of BEZ235 SDS as single agent and in combination with trastuzumab administered to patients at the MTD level (Safety expansion part)Time frame: at end of study
Locations
15 sites in 5 countries. Site status is shown where the registry gives one.
University of California at Los Angeles JonssonComprehensiveCancerCtr
Los Angeles, California
Yale University School of Medicine YaleCancerCtr-ClinTrialsOffice
New Haven, Connecticut
Dana Farber Cancer Institute Clinical Trials ProjectManager
Boston, Massachusetts
Nevada Cancer Institute NVCC - Huntsman
Las Vegas, Nevada
Cancer Centers of the Carolinas CCC Faris
Greenville, South Carolina
Sarah Cannon Research Institute Dept.ofSarahCannonCancerCtr(2)
Nashville, Tennessee
Baylor Health Care System/Sammons Cancer Center Baylor- Sammons
Dallas, Texas
University of Texas/MD Anderson Cancer Center Thoractic Head/Neck Med.Onc(2)
Houston, Texas
Tyler Cancer Center TCC
Tyler, Texas
Novartis Investigative Site
Essen, Germany
Novartis Investigative Site
Amsterdam, Netherlands
Novartis Investigative Site
Barcelona, Catalonia, Spain
Novartis Investigative Site
Valencia, Valencia, Spain
Novartis Investigative Site
Valencia, Valencia, Spain
Novartis Investigative Site
Manchester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.